Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
Identifieur interne : 000078 ( Main/Curation ); précédent : 000077; suivant : 000079Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
Auteurs : Nir Giladi [Israël] ; Liesbet Ghys [Belgique] ; Erwin Surmann [Allemagne] ; Babak Boroojerdi [États-Unis] ; Joseph Jankovic [États-Unis]Source :
- Parkinsonism & related disorders ; 2014.
English descriptors
- KwdEn :
- Administration, Cutaneous, Adult, Age Factors, Aged, Aged, 80 and over, Antiparkinson Agents (administration & dosage), Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Dyskinesias (diagnosis), Dyskinesias (epidemiology), Dyskinesias (etiology), Female, Humans, Kaplan-Meier Estimate, Levodopa (therapeutic use), Longitudinal Studies, Male, Middle Aged, Parkinson Disease (drug therapy), Sex Factors, Tetrahydronaphthalenes (administration & dosage), Thiophenes (administration & dosage).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Tetrahydronaphthalenes, Thiophenes.
- diagnosis : Dyskinesias.
- drug therapy : Parkinson Disease.
- epidemiology : Dyskinesias.
- etiology : Dyskinesias.
- chemical , therapeutic use : Levodopa.
- Administration, Cutaneous, Adult, Age Factors, Aged, Aged, 80 and over, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Kaplan-Meier Estimate, Longitudinal Studies, Male, Middle Aged, Sex Factors.
Abstract
In two 6-month, double-blind, placebo-controlled studies, rotigotine transdermal system was well-tolerated and efficacious monotherapy in early-stage PD. This post hoc analysis of the long-term open-label extensions (NCT00594165; NCT00599196) of these studies assessed incidence and severity of dyskinesia in participants treated with rotigotine, with or without concomitant levodopa, for up to 6 years.
DOI: 10.1016/j.parkreldis.2014.09.016
PubMed: 25444083
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000019
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000019
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000036
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000478
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000478
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000478
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :000078
Links to Exploration step
pubmed:25444083Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.</title><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Tel-Aviv University, Tel-Aviv, Israel; Sago School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: nirg@tlvmc.gov.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Tel-Aviv University, Tel-Aviv, Israel; Sago School of Neuroscience, Tel-Aviv University, Tel-Aviv</wicri:regionArea><wicri:noRegion>Tel-Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Ghys, Liesbet" sort="Ghys, Liesbet" uniqKey="Ghys L" first="Liesbet" last="Ghys">Liesbet Ghys</name><affiliation wicri:level="3"><nlm:affiliation>UCB Pharma, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB Pharma, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Surmann, Erwin" sort="Surmann, Erwin" uniqKey="Surmann E" first="Erwin" last="Surmann">Erwin Surmann</name><affiliation wicri:level="1"><nlm:affiliation>UCB Pharma, Monheim am Rhein, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>UCB Pharma, Monheim am Rhein</wicri:regionArea><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion></affiliation></author><author><name sortKey="Boroojerdi, Babak" sort="Boroojerdi, Babak" uniqKey="Boroojerdi B" first="Babak" last="Boroojerdi">Babak Boroojerdi</name><affiliation wicri:level="2"><nlm:affiliation>UCB Biosciences Inc., Raleigh, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UCB Biosciences Inc., Raleigh, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25444083</idno><idno type="pmid">25444083</idno><idno type="doi">10.1016/j.parkreldis.2014.09.016</idno><idno type="wicri:Area/PubMed/Corpus">000019</idno><idno type="wicri:Area/PubMed/Curation">000019</idno><idno type="wicri:Area/PubMed/Checkpoint">000036</idno><idno type="wicri:Area/Ncbi/Merge">000478</idno><idno type="wicri:Area/Ncbi/Curation">000478</idno><idno type="wicri:Area/Ncbi/Checkpoint">000478</idno><idno type="wicri:Area/Main/Merge">000078</idno><idno type="wicri:Area/Main/Curation">000078</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.</title><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Tel-Aviv University, Tel-Aviv, Israel; Sago School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: nirg@tlvmc.gov.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Tel-Aviv University, Tel-Aviv, Israel; Sago School of Neuroscience, Tel-Aviv University, Tel-Aviv</wicri:regionArea><wicri:noRegion>Tel-Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Ghys, Liesbet" sort="Ghys, Liesbet" uniqKey="Ghys L" first="Liesbet" last="Ghys">Liesbet Ghys</name><affiliation wicri:level="3"><nlm:affiliation>UCB Pharma, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB Pharma, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Surmann, Erwin" sort="Surmann, Erwin" uniqKey="Surmann E" first="Erwin" last="Surmann">Erwin Surmann</name><affiliation wicri:level="1"><nlm:affiliation>UCB Pharma, Monheim am Rhein, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>UCB Pharma, Monheim am Rhein</wicri:regionArea><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion></affiliation></author><author><name sortKey="Boroojerdi, Babak" sort="Boroojerdi, Babak" uniqKey="Boroojerdi B" first="Babak" last="Boroojerdi">Babak Boroojerdi</name><affiliation wicri:level="2"><nlm:affiliation>UCB Biosciences Inc., Raleigh, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UCB Biosciences Inc., Raleigh, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><series><title level="j">Parkinsonism & related disorders</title><idno type="e-ISSN">1873-5126</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (administration & dosage)</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Dyskinesias (diagnosis)</term><term>Dyskinesias (epidemiology)</term><term>Dyskinesias (etiology)</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Levodopa (therapeutic use)</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Sex Factors</term><term>Tetrahydronaphthalenes (administration & dosage)</term><term>Thiophenes (administration & dosage)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Tetrahydronaphthalenes</term><term>Thiophenes</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Sex Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In two 6-month, double-blind, placebo-controlled studies, rotigotine transdermal system was well-tolerated and efficacious monotherapy in early-stage PD. This post hoc analysis of the long-term open-label extensions (NCT00594165; NCT00599196) of these studies assessed incidence and severity of dyskinesia in participants treated with rotigotine, with or without concomitant levodopa, for up to 6 years.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000078 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000078 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:25444083
|texte= Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:25444083" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |